May 15, 2013, 2:45 PM EDT
San Diego State landed a huge commitment on Wednesday afternoon as Tulane transfer Josh Davis decided that he will play his final collegiate season as an Aztec.
Davis began his career at NC State, transferring to Tulane and sitting out the 2010-2011 season. As a redshirt junior, he averaged 17.6 points and 10.9 boards with the Green Wave, and since he has graduated, he will be eligible to play immediately.
Davis is a 6-foot-8, athletic forward that will certainly help SDSU replace the scoring that they lose with Chase Tapley’s graduation and Jamaal Franklin heading off to the NBA.
It’s no secret that SDSU needed to bolster their front court for this season, which is precisely what Davis will do as SDSU waits for Arizona transfer Angelo Chol to become eligible. It’s also not a secret that lanky, athletic forwards tend to thrive under Steve Fisher, and again, that’s precisely what Davis.
SDSU beat out Gonzaga for Davis. The Zags were also on the wrong end of the Mike Moser sweepstakes. With Kelly Olynyk and Elias Harris graduating, Mark Few really could have used one of those front court bodies next season.
You can find Rob on twitter @RobDauster.
- CBT’s Recruiting Roundup: Washington’s big Monday, Maryland’s insurance, Two 2016 guards off board 0
- Top 25 Countdown: No. 15 Oklahoma Sooners 0
- 2014-2015 Season Preview: Which new coaching hires will succeed? 0
- No longer supplementary pieces, two Texans will lead the way at Weber State 0
- 2014-2015 Season Preview: Weber State won’t lack for challengers in Big Sky 0
- Led by senior forward Alan Williams, UCSB capable of earning first NCAA tournament bid since 2011 0
- Behind Thompson and Comer, Dunk City looks to take flight once again this March 0
- Big Ten writers release media poll, Wisconsin sits atop the league (6)
- First Preseason Top 25 poll is out, Kentucky sits at No. 1 (2)
- Maryland senior forward suffers sprained ankle (2)
- 2014-2015 Season Preview: Mid-Major Power Rankings (1)
- NCAA approves waiver to allow player with terminal cancer to play (1)